Stay updated with breaking news from Human Igg. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BA.2.75 is an emerging omicron variant that has been classed as a variant of interest by the WHO. ACROBiosystems has developed a huge range of antigen products, including Spike trimers and nucleocapsid proteins to help with research into the omicron variant.
In this article, ACROBiosystems discusses BA.2.75, a newly emerging SARS-CoV-2 variant with surprising transmission speed, and the potential ramifications this has against the ongoing fight against COVID-19.
In this article, ACROBiosystems discusses COVID-19, specifically omicron recombinants and how this could lead to new, infectious strains emerging.
In this article, ACROBiosystems demonstrates how DLL-3 could become a potential target for a variety of lung cancer therapies.
1 Abstract The devastating Ebola outbreak in West Africa in 2013-2016 accelerated the progress of several medical countermeasures (MCMs) against Ebola virus disease (EVD). Several IPs were used during that outbreak, but no conclusion on efficacy could be drawn. Only the Randomized Controlled Trial (RCT) on ZMapp was promising but inconclusive. More recently, during the second largest Ebola outbreak in North Kivu and Ituri provinces, Democratic Republic of the Congo (DRC), four IPs (Remdesivir, Regeneron, ZMapp and MAb114) have been evaluated in a RCT, the Pamoja Tulinde Maisha (PALM) study. Tw...